Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice.

Mol Neurodegener · 2013 · PMC3693923 · PMID 23764200

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an unexplained trendno p-value reported

However, we again observed an unexplained trend of freezing deficit in non-transgenic males treated with bexarotene as compared to vehicle- and bexarotene-treated APP swe / PS1 ΔE9 males (Figure 3 B).

also in 5 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.